4.8 Review

The double-edged roles of ROS in cancer prevention and therapy

期刊

THERANOSTICS
卷 11, 期 10, 页码 4839-4857

出版社

IVYSPRING INT PUBL
DOI: 10.7150/thno.56747

关键词

-

资金

  1. National Natural Science Foundation of China [82073286, 81672440, 81972625]
  2. Construction of Liaoning Cancer Research Center (Lung Cancer) [2019JH6/10200011]
  3. Technological Special Project of Liaoning Province of China [2019020176-JH1/103]
  4. Central financial fund for promoting medical service and safeguarding capability (Capability construction of medical and health organizations)
  5. Liaoning Cancer Hospital

向作者/读者索取更多资源

Reactive oxygen species (ROS) act as cell signaling molecules generated in oxidative metabolism and are associated with various human diseases. Abnormal accumulation of ROS in cancer cells leads to tumor progression and metastasis. Understanding the dual roles of ROS in tumor growth, metastasis, and apoptosis, as well as related signal transduction networks and anticancer therapies is crucial in conquering cancer.
Reactive oxygen species (ROS) serve as cell signaling molecules generated in oxidative metabolism and are associated with a number of human diseases. The reprogramming of redox metabolism induces abnormal accumulation of ROS in cancer cells. It has been widely accepted that ROS play opposite roles in tumor growth, metastasis and apoptosis according to their different distributions, concentrations and durations in specific subcellular structures. These double-edged roles in cancer progression include the ROS-dependent malignant transformation and the oxidative stress-induced cell death. In this review, we summarize the notable literatures on ROS generation and scavenging, and discuss the related signal transduction networks and corresponding anticancer therapies. There is no doubt that an improved understanding of the sophisticated mechanism of redox biology is imperative to conquer cancer.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.8
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据